Abstract
The aim of this study was to evaluate the safety and clinical effectiveness of rhBMP-7 (or osteogenic protein-1) versus that of autogenous iliac crest bone graft (ICBG) in single-level posterolateral fusion (PLF) of the lumbar spine. A systematic search of all articles published through July 1, 2016 was conducted in databases such as PubMed, EMBASE, Scopus, and the Cochrane Collaboration Library. Randomized controlled trials (RCTs) that compared rhBMP-7 with ICBG for the treatment of single-level degenerative spondylolisthesis, provided the fusion rate, clinical success rate, safety and adverse events report, operation time, and hospital stay durations as the outcome were assessed. As a result, a total of five RCTs involving 539 patients met the inclusion criteria. The outcomes of subgroup analysis demonstrated that when compared with autogenous ICBG, rhBMP-7 appear to yield lower fusion rates in instrumented posterolateral fusion patients (RR = 0.76, 95% CI [0.60, 0.98], P = 0.03), despite the test for overall fusion rates suggested that there was no significant difference between the two groups (RR = 0.89, 95% CI [0.78, 1.02], P = 0.09). Patients treated with OP-1 had shorter operation times versus those treated with ICBG (WMD = −16.70,95% CI [−25.83, −7.57], P = 0.0003). Additionally, the outcomes demonstrated a lack of significant differences between rhBMP-7 and ICBG in terms of clinical success of ODI, overall adverse events, revision rates and duration of hospitalization. In conclusion, with the exception of reducing the operation time, our review suggests that the use of the rhBMP-7 instead of ICBG produce no any additional beneficial effect on the fusion rates, clinical success of ODI, overall adverse events, revision rates and duration of hospitalization in single level PLF. On the contrary, it appeared to yield lower fusion rate in the instrumented posterolateral fusion patients and cannot be recommended as an effective tool for this set of patients.
Similar content being viewed by others
References
Deyo RA, Nachemson A, Mirza SK (2004) Spinal-fusion surgery: the case for restraint. N Engl J Med 350:722–726
Ito Z, Imagama S, Kanemura T et al (2013) Bone union rate with autologous iliac bone versus local bone graft in posterior lumbar interbody fusion (PLIF): a multicenter study. Eur Spine J 22:1158–1163
Kim DH, Rhim R, Li L et al (2009) Prospective study of iliac crest bone graft harvest site pain and morbidity. Spine J 9:886–892
Schwartz CE, Martha JF, Kowalski P et al (2009) Prospective evaluation of chronic pain associated with posterior autologous iliac crest bone graft harvest and its effect on postoperative outcome. Health Qual Life Outcomes 7:49
Silber JS, Anderson DG, Daffner SD, et al (2003) Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 28:134–139
Cook SD, Wolfe MW, Salkeld SL et al (1995) Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 77:734–750
Ong K L, Villarraga ML, Lau E et al (2010) Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 35:1794–1800
Meyerding HW (1956) Spondylolisthesis; surgical fusion of lumbosacral portion of spinal column and interarticular facets; use of autogenous bone grafts for relief of disabling backache. J Int Coll Surg 26:566–591
Walsh TL, Hanscom B, Lurie JD, et al (2003) Is a condition-specific instrument for patients with low back pain/leg symptoms really necessary? The responsiveness of the Oswestry Disability Index, MODEMS, and the SF-36. Spine (Phila Pa 1976) 28:607–615
Verhagen AP, de Vet HC, de Bie RA et al (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235–1241
Delawi D, Dhert WJ, Rillardon L et al (2010) A prospective, randomized, controlled, multicenter study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety and feasibility. Spine (Phila Pa 1976) 35:1185–1191
Vaccaro AR, Lawrence JP, Patel T, et al (2008) The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine (Phila Pa 1976) 33:2850–2862
Vaccaro AR, Whang PG, Patel T et al (2008) The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 8:457–465
Kanayama M, Hashimoto T, Shigenobu K et al (2006) A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 31:1067–1074
Vaccaro AR, Anderson DG, Patel T et al (2005) Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976) 30:2709–2716
Vaccaro AR, Patel T, Fischgrund J et al (2005) A 2-year follow-up pilot study evaluating the safety and efficacy of op-1 putty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J 14:623–629
Vaccaro AR, Patel T, Fischgrund J et al (2004) A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976) 29:1885–1892
Johnsson R, Stromqvist B, Aspenberg P (2002) Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 27:2654–2661
Hwang CJ, Vaccaro AR, Hong J et al (2010) Immunogenicity of osteogenic protein 1: results from a prospective, randomized, controlled, multicenter pivotal study of uninstrumented lumbar posterolateral fusion. J Neurosurg Spine 13:484–493
Delawi D, Jacobs W, van Susante JL et al (2016) OP-1 compared with iliac crest autograft in instrumented posterolateral fusion: a randomized, multicenter non-inferiority trial. J Bone Joint Surg Am 98:441–448
Guerado E, Cervan AM (2012) Surgical treatment of spondylodiscitis. An update. Int Orthop 36:413–420
Hempelmann RG, Mater E, Schon R (2010) Septic hematogenous lumbar spondylodiscitis in elderly patients with multiple risk factors: efficacy of posterior stabilization and interbody fusion with iliac crest bone graft. Eur Spine J 19:1720–1727
Jenis LG, Wheeler D, Parazin SJ et al (2002) The effect of osteogenic protein-1 in instrumented and noninstrumented posterolateral fusion in rabbits. Spine J 2:173–178
Owens K, Glassman SD, Howard JM et al (2011) Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur Spine J 20:612–617
Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11:471–491
Kokorina NA, Lewis JJ, Zakharkin SO et al (2012) rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo. Laryngoscope 122:95–102
Gao Q, Tong W, Luria JS et al (2010) Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 39:266–271
Rothhammer T, Poser I, Soncin F et al (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448–456
Chirasani SR, Sternjak A, Wend P et al (2010) Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133:1961–1972
Piccirillo SG, Vescovi AL (2006) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 5:59–81
Piccirillo SG, Reynolds BA, Zanetti N et al (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
There are no identified conflicts of interest with any of the authors.
Additional information
F. Ye and Z. Zeng contributed equally to this work and shared first authroship.
About this article
Cite this article
Ye, F., Zeng, Z., Wang, J. et al. Comparison of the use of rhBMP-7 versus iliac crest autograft in single-level lumbar fusion: a meta-analysis of randomized controlled trials. J Bone Miner Metab 36, 119–127 (2018). https://doi.org/10.1007/s00774-017-0821-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-017-0821-z